On March 21, the quadrivalent influenza virus split vaccine, a Biological Product independently developed by Anhui Zhifei Longkema, a wholly-owned subsidiary of Chongqing Zhifei Biological Products, received the "Drug Registration Certificate" issued by the National Medical Products Administration. This vaccine is intended for individuals aged 3 and older.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Hong Kong media: CKH HOLDINGS' plan to sell the port is postponed, and no contract will be signed next week.
The State Administration for Market Regulation: Conducting an examination of CKH HOLDINGS port Trade in accordance with the law.
U.S. Stock Market Preview | Core PCE exceeded expectations, with three major futures indices declining in the short term; Tesla rose nearly 1% in pre-market trading, while Musk stated that Trump would hold those who attacked Tesla accountable; AppLovin re
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
智飞生物四价流感病毒裂解疫苗获批上市
Chongqing Zhifei Biological Products' quadrivalent influenza virus split vaccine has been approved for marketing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 212
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report